Compared side by side

HGH vs tesamorelin: how they differ

Reviewed How we check the libraryPublished by PepVault

The short answer

HGH is recombinant growth hormone itself; tesamorelin is a synthetic GHRH analogue that stimulates the body’s own GH secretion. Both are FDA-approved for narrow uses: HGH for GH deficiency and several growth disorders, tesamorelin to reduce excess abdominal fat in HIV lipodystrophy, where in two phase 3 trials it cut visceral fat about 15% in 26 weeks. Both are daily shots.

Side by side

ComparedHGHTesamorelin
CategoryGrowth hormoneGrowth hormone
Also known asGH, rHGH, Human Growth Hormone, Growth Hormone, Somatropin, hGHEgrifta
What it isRecombinant human growth hormone — an identical copy of the GH your pituitary makes.The only GHRH analog currently FDA-approved (to reduce excess abdominal fat in HIV lipodystrophy).
How it worksRecombinant human growth hormone. Binds GH receptors to stimulate IGF-1 production, protein synthesis, and lipolysis. Promotes muscle growth, fat oxidation, and tissue repair. Structurally identical to pituitary GH, though injections don't reproduce its natural pulses.Synthetic GHRH analogue FDA-approved for HIV-associated lipodystrophy. Stimulates GH secretion, reduces visceral adiposity, and improves body composition. Its half-life is short, close to sermorelin's (8–11 minutes on the current labels).
Commonly reportedWater retention, numb or tingling fingers, joint aches, and better sleep and skin. Requires careful dosing and IGF-1 monitoring — more is not always better.Waist and belly shrinking while body weight barely moves, with injection-site redness and early joint aches.
Studied rangeResearch range: 1–4 IU. Studied in research — not a recommendation.Research range: 1–2 mg. Studied in research — not a recommendation. FDA-approved as Egrifta WR (1.28 mg) and Egrifta SV (1.4 mg), SubQ once daily, to reduce excess abdominal fat in adults with HIV lipodystrophy.
How oftenDaily SubQ injection.Daily
Half-life~3-4 hours (SubQ)~8–11 min (current EGRIFTA SV/WR labels; the original label listed ~26 min)
RouteSubQ injectionSubQ injection
Typical runCommonly reported starting dose 1-2 IU daily. Advanced users may run 3-4 IU split AM/PM. Cycles of 3-6+ months common. Monitor IGF-1 levels. Also run alongside peptide stacks; some advanced protocols add insulin, which isn't in this library.FDA approval context: daily use. Community typically runs 12–24 weeks. Reassess at 3 months.
EvidenceEstablished: clinical trials or FDA-approved use existsEstablished: clinical trials or FDA-approved use exists
Common side effectsWater retention, joint pain, carpal tunnel syndrome, morning fatigue, injection site reactionsInjection site reaction, fluid retention, joint pain, nausea, glucose dysregulation

Typical run: Community practice — opinions vary. Not a clinical recommendation.

A smiling man in a grey t-shirt in his living room, holding his phone

PepVault for iPhone

Taking HGH or tesamorelin? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Week by week

Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.

HGH

Week-by-week cards for HGH are not in our library.

Every card for HGH, with its sources

Tesamorelin

  • Day 1–14 Targeting the deep belly fat
  • Day 14–56 Visceral fat is mobilizing

Every card for tesamorelin, with its sources

Questions people ask

How long do HGH and tesamorelin last?

The half-life of HGH is ~3-4 hours (SubQ). The half-life of tesamorelin is ~8–11 min (current EGRIFTA SV/WR labels; the original label listed ~26 min).

How often are HGH and tesamorelin taken?

HGH: daily SubQ injection. Route: SubQ injection. Tesamorelin: daily. Route: SubQ injection.

How are HGH and tesamorelin dosed in research?

The research range for HGH is 1–4 IU. Studied in research — not a recommendation. The research range for tesamorelin is 1–2 mg. Studied in research — not a recommendation. FDA-approved as Egrifta WR (1.28 mg) and Egrifta SV (1.4 mg), SubQ once daily, to reduce excess abdominal fat in adults with HIV lipodystrophy.

What are the common side effects of HGH and tesamorelin?

For HGH, the library lists: water retention, joint pain, carpal tunnel syndrome, morning fatigue, injection site reactions. For tesamorelin: injection site reaction, fluid retention, joint pain, nausea, glucose dysregulation.

Each one in full

Track it in the app

PepVault for iPhone

Taking HGH or tesamorelin? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo